Mycophenolate Use in Reproductive-Aged Patients – What Every Osteopathic Clinician Should Know

Create Account

Availability

On-Demand

Access expires on Nov 23, 2026

Cost

$0.00

Credit Offered

1.5 AMA PRA Category 1 Credits

1.5 AOA Category 1-B Credits

OVERVIEW
There is a critical and well-documented gap in clinician awareness and patient counseling regarding the embryofetal toxicity risks associated with mycophenolate use during pregnancy. Despite established evidence linking prenatal exposure to significantly increased risks of first-trimester pregnancy loss and congenital malformations, current clinical practices often lack consistent implementation of risk mitigation strategies. This gap compromises patient safety, particularly among reproductive-age individuals who may not receive adequate counseling on pregnancy prevention or informed decision-making prior to initiating therapy. This interactive, case-based activity will target awareness, counseling protocols, and risk mitigation.

OBJECTIVES

Recognize the increased risks of first trimester pregnancy loss and congenital malformations associated with mycophenolate use
Explain the risks of mycophenolate exposure during pregnancy to patients
Demonstrate effective patient education on pregnancy prevention, including appropriate contraceptive methods during treatment
Identify alternative immunosuppressive therapies with lower embryofetal risk for use in pregnancy or preconception planning
Describe the process for reporting pregnancies to the Mycophenolate Pregnancy Registry per REMS requirements
Review approaches to encourage patient participation in the registry to contribute to safety monitoring and research

Expiration Date: November 23, 2026

The American Osteopathic Association (AOA) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Osteopathic Internists (ACOI) designates this activity for a maximum of 1.5 AOA Category 1-B Credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.